Day 1 - Morning

Group 1A: Inflammatory Breast Cancer; Triple Negative Breast Cancer; Black Populations Sold Out

Group 1B: HER2-low, HER2-0, & HR+ Breast Cancer; Clinical Trials Sold Out

Group 1C: BRCA+ Breast Cancer; Clinical Trials; Oncofertility; Younger Populations

Group 1D: Brain Metastasis; Novel Targets

Group 1E: ER+ Breast Cancer; Younger Populations; Quality of Life

Group 1F: HER2+ Breast Cancer; Triple Positive Breast Cancer; Clinical Trials; Treatment Resistance Sold Out